NASDAQ : MLTX
MoonLake Immunotherapeutics — Company profile
Healthcare · Biotechnology · Switzerland
Last price 11.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.00B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Details
| Name | MoonLake Immunotherapeutics |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 130 |
| Founded | 2021 |
| Ceo | Jorge da Silva |
| Country | Switzerland |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | KY61559X1045 |
| Cusip | 61559X104 |
| Cik | 1821586 |
| Sic | 2834 |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board and Chief Executive Officer |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop Ph.D. | Chief Technical Officer |
| Carla Bretes | Director of Investor Relations and External Communications |
| Nicolas Mosimann Ph.D. | General Counsel |
| Joana Cortez | Associate Vice-President of Legal and Compliance |
| Tino Anthamatten | Vice President of Marketing, Market Access and Pricing |
| Luciana Marques | Associate Vice-President of Human Resources, People and Culture |
| Nuala Brennan | Chief Clinical Development Officer |
Contact
| Address | Dorfstrasse 29, Zug, 6300, Switzerland |
| Phone | 41 415108022 |
| Website | https://www.moonlaketx.com |